<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519428</url>
  </required_header>
  <id_info>
    <org_study_id>5476</org_study_id>
    <secondary_id>5R01MH076961-04</secondary_id>
    <nct_id>NCT00519428</nct_id>
  </id_info>
  <brief_title>Does Dual Therapy Hasten Antidepressant Response?</brief_title>
  <official_title>Combining Antidepressants to Hasten Remission From Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will utilize a randomized double-blind design to evaluate whether initial
      treatment with two anti-depressant medications (escitalopram and bupropion) results in more
      rapid remission and greater over-all remission rates than either monotherapy in 240 depressed
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is a major public health problem due to its prevalence and accompanying
      dysfunction and costs. Depression is undertreated, but even when treatment is adequate and
      effective, sources of delay in current pharmacologic strategies include: mechanistic delays,
      those related to the physiologic and behavioral effects of antidepressants; dosing delays in
      identifying the effective dose; and programmatic delays in identifying an effective agent
      using sequential monotherapy. This study will randomize 240 patients with Diagnostic and
      Statistical Manual, 4th Edition (DSM-IV) Major Depressive Disorder (MDD) to 12 week double
      blind treatment with combined escitalopram and bupropion or each antidepressant administered
      alone to evaluate whether combined escitalopram and bupropion result in more rapid remission
      and greater over-all remission than monotherapy. Preclinical and clinical studies suggest
      that bupropion might prevent one mechanistic delay inherent in escitalopram monotherapy.
      Rapid dose escalation may counter dosing delays. The simultaneous use of two known
      antidepressant medications may alleviate programmatic delays inherent in usual sequential
      monotherapy. Six months follow up and careful assessment of adverse events will address
      tolerability, acceptability, sustainability, and pharmacoeconomic concerns. If successful,
      this study might have a significant impact on clinical practice, public health, and
      depression's cost consequences.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) &lt;= 7, With no Subsequent HAM-D 17 &gt; 7</measure>
    <time_frame>12 weeks</time_frame>
    <description>Life Table Survival Analysis run twice, once comparing Dual Therapy (i.e., Bupropion + Escitalopram) to Bupropion alone (i.e., Bupropion + Placebo) and once comparing Dual Therapy to Escitalopram alone (i.e., Escitalopram + Placebo). Because both analyses must significantly favor Dual Therapy, each individual analysis must reach a critical alpha = .0916 in order to reach an over-all alpha = .05.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission: Persistent Hamilton Rating Scale for Depression, 17 Items (HAM-D 17) &lt;= 7, With no HAM-D 17 &gt;7 Through Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Chi square comparison of rates of persistent remission (i.e., no subsequent Hamilton Rating Scale for Depression, 17 items [HAMD-D 17] &gt; 7 once HAMD-D 17 &lt;= 7); Dual rate vs. Escitalopram only rate and Dual rate vs. Bupropion only rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Depressive Symptoms as Measured by Hamilton Rating Scale for Depression (HAM-D 17)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Last summary score rating on the 17-item Hamilton Rating Scale for Depression Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Range 0-58.
0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression
≥ 23 = Very Severe Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functioning, as Measured by the Social Adjustment Scale (SAS) Summary Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Social adjustment was measured using the Social Adjustment Scale (SAS). The SAS is a self-report scale that assesses depressive symptoms and functioning in nine social and work-related domains generating a total score that is indicative of a subject's overall level of social adjustment. Subjects rate their own social functioning over times on a 5-point scale on items covering work for pay, housework, extended family, parenting, marital status, social activity and leisure, family unit and student status (sub-scales). Mean values of all the sub-scales are used, with a range from 0-5. Higher score = worse outcome … worse functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (SF)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) intends to measure quality of life in 16 domains. A summary score is computed by adding the scores and dividing by 16 (or the number of answered items if some are not answered).
The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70. Higher score means more satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>escitalopram + bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escitalopram plus bupropion extra long (XL) as dual treatment (i.e., this is not a SINGLE treatment arm; all patients assigned this arm received both medications)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>escitalopram monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bupropion extra long (XL) monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted</description>
    <arm_group_label>escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion extra long (XL)</intervention_name>
    <description>150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted</description>
    <arm_group_label>bupropion</arm_group_label>
    <other_name>Wellbutrin extra long (XL)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram + bupropion</intervention_name>
    <description>same dosing schedule as for monotherapy</description>
    <arm_group_label>escitalopram + bupropion</arm_group_label>
    <other_name>Lexapro</other_name>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ages 18-65

          2. Major Depressive Disorder as primary diagnosis

          3. Physically healthy

          4. Signs informed consent

          5. Montgomery Asberg Depression Rating Scale (MADRS) &gt;= 22

        Exclusion Criteria:

          1. Bipolar Disorder (ie, Bipolar I, Bipolar II, Bipolar NOS)

          2. Life-time history of psychosis

          3. Current (ie, last 6 months) drug or alcohol abuse or dependence (except nicotine)

          4. Currently taking effective antidepressant medication

          5. Prior adequate treatment in current depressive episode with a selective serotonin
             re-uptake inhibitor (SSRI), bupropion (BUP) or bupropion (BUP) + a selective serotonin
             re-uptake inhibitor (SSRI) (&quot;adequate&quot; is defined as &gt;= 4 weeks taking &gt;= 2/3
             Physician's Desk Reference (PDR) maximal dose

          6. Most recent antidepressant was within 5 weeks for fluoxetine and 1 week for all others

          7. Currently taking a medication contraindicated with either study medication

          8. Life time history of anorexia or bulimia

          9. Life time history of seizure or known increased seizure risk (e.g., history of
             significant brain trauma, taking pro-convulsant medication, known anatomical brain
             lesion)

         10. Currently taking psychoactive medication deemed to be necessary (including but not
             limited anticonvulsants, antidepressants, antipsychotics, steroids, and B-blockers);
             occasional use of hypnotics (ie, less than three times per week) will be allowed

         11. Unstable medical condition (ie, condition not adequately stabilized for &gt;= 3 months)

         12. Prior intolerance to escitalopram (ESC) or bupropion (BUP)

         13. Inadequate understanding of English (for US site; Canadian site permits French
             fluency)

         14. Currently pregnant or breast-feeding; fecund women not using adequate contraceptive
             methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan W. Stewart, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Blier, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ottawa, Institute of Mental Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa, Institute of Mental Health Research</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Z7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depression-nyc.org/</url>
    <description>Depression Evaluation Service official website</description>
  </link>
  <link>
    <url>https://www.columbiapsychiatry.org/</url>
    <description>Columbia University Depart,ment of Psychiatry web page</description>
  </link>
  <link>
    <url>http://www.imhr.ca</url>
    <description>official website of the University of Ottawa's Institute of Mental Health Research</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2007</study_first_submitted>
  <study_first_submitted_qc>August 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2007</study_first_posted>
  <results_first_submitted>October 6, 2016</results_first_submitted>
  <results_first_submitted_qc>September 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2017</results_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment dates: August, 2007 to August 2011 Locations: 4 outpatient research clinics in two countries (US and Canada)</recruitment_details>
      <pre_assignment_details>All patients had to be psychoactive drug-free for at least two weeks (five weeks for fluoxetine) prior to randomization and had to continue to meet study entry criteria at point of randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram + Bupropion</title>
          <description>escitalopram plus bupropion</description>
        </group>
        <group group_id="P2">
          <title>Escitalopram</title>
          <description>escitalopram monotherapy</description>
        </group>
        <group group_id="P3">
          <title>Bupropion</title>
          <description>bupropion monotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unstated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram + Bupropion</title>
          <description>escitalopram plus bupropion XL</description>
        </group>
        <group group_id="B2">
          <title>Escitalopram</title>
          <description>escitalopram monotherapy</description>
        </group>
        <group group_id="B3">
          <title>Bupropion</title>
          <description>bupropion XL monotherapy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="83"/>
            <count group_id="B4" value="245"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Patient's report of their age</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="10"/>
                    <measurement group_id="B2" value="41" spread="11"/>
                    <measurement group_id="B3" value="40" spread="11"/>
                    <measurement group_id="B4" value="40" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) &lt;= 7, With no Subsequent HAM-D 17 &gt; 7</title>
        <description>Life Table Survival Analysis run twice, once comparing Dual Therapy (i.e., Bupropion + Escitalopram) to Bupropion alone (i.e., Bupropion + Placebo) and once comparing Dual Therapy to Escitalopram alone (i.e., Escitalopram + Placebo). Because both analyses must significantly favor Dual Therapy, each individual analysis must reach a critical alpha = .0916 in order to reach an over-all alpha = .05.</description>
        <time_frame>12 weeks</time_frame>
        <population>age 18-65 with Major Depressive Disorder (MDD), non-bipolar, non-psychotic, non-substance abusing, without intolerance to study drugs or adequate selective serotonin re-uptake inhibitor (SSRI) and/or bupropion treatment in current episode; physically healthy without contraindications to bupropion or escitalopram.</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram + Bupropion</title>
            <description>escitalopram plus bupropion XL</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram</title>
            <description>escitalopram monotherapy</description>
          </group>
          <group group_id="O3">
            <title>Bupropion</title>
            <description>bupropion XL monotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) &lt;= 7, With no Subsequent HAM-D 17 &gt; 7</title>
          <description>Life Table Survival Analysis run twice, once comparing Dual Therapy (i.e., Bupropion + Escitalopram) to Bupropion alone (i.e., Bupropion + Placebo) and once comparing Dual Therapy to Escitalopram alone (i.e., Escitalopram + Placebo). Because both analyses must significantly favor Dual Therapy, each individual analysis must reach a critical alpha = .0916 in order to reach an over-all alpha = .05.</description>
          <population>age 18-65 with Major Depressive Disorder (MDD), non-bipolar, non-psychotic, non-substance abusing, without intolerance to study drugs or adequate selective serotonin re-uptake inhibitor (SSRI) and/or bupropion treatment in current episode; physically healthy without contraindications to bupropion or escitalopram.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="7"/>
                    <measurement group_id="O2" value="9" spread="7"/>
                    <measurement group_id="O3" value="10" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hypothesis: Dual Treatment (escitalopram + bupropion) will result in greater improvement over 12 weeks than either monotherapy (i.e., two analyses: 1) dual treatment will outperform escitalopram monotherapy; 2) dual treatment will outperform bupropion monotherapy). Therefore each analysis will be done twice and it will be required that both analyses be significant to declare the over-all study significant.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Hypothesis: Dual Treatment (escitalopram + bupropion) will result in greater improvement over 12 weeks than either monotherapy (i.e., two analyses: 1) dual treatment will outperform escitalopram monotherapy; 2) dual treatment will outperform bupropion monotherapy).</non_inferiority_desc>
            <p_value>.05</p_value>
            <p_value_desc>Each individual test will require the calculated &quot;p&quot; to be &lt; .0916 to declare that comparison to be significant. Since the hypothesis requires both comparisons to be significant, this produces an over-all alpha of .05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.05</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission: Persistent Hamilton Rating Scale for Depression, 17 Items (HAM-D 17) &lt;= 7, With no HAM-D 17 &gt;7 Through Week 12</title>
        <description>Chi square comparison of rates of persistent remission (i.e., no subsequent Hamilton Rating Scale for Depression, 17 items [HAMD-D 17] &gt; 7 once HAMD-D 17 &lt;= 7); Dual rate vs. Escitalopram only rate and Dual rate vs. Bupropion only rate.</description>
        <time_frame>12 weeks</time_frame>
        <population>age 18-65 with MDD, non-bipolar, non-psychotic, non-substance abusing, without intolerance to study drugs or adequate SSRI/bupropion treatment in current episode; physically healthy without contraindications to bupropion or escitalopram.</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram + Bupropion</title>
            <description>escitalopram plus bupropion XL</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram</title>
            <description>escitalopram monotherapy</description>
          </group>
          <group group_id="O3">
            <title>Bupropion</title>
            <description>bupropion XL monotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Remission: Persistent Hamilton Rating Scale for Depression, 17 Items (HAM-D 17) &lt;= 7, With no HAM-D 17 &gt;7 Through Week 12</title>
          <description>Chi square comparison of rates of persistent remission (i.e., no subsequent Hamilton Rating Scale for Depression, 17 items [HAMD-D 17] &gt; 7 once HAMD-D 17 &lt;= 7); Dual rate vs. Escitalopram only rate and Dual rate vs. Bupropion only rate.</description>
          <population>age 18-65 with MDD, non-bipolar, non-psychotic, non-substance abusing, without intolerance to study drugs or adequate SSRI/bupropion treatment in current episode; physically healthy without contraindications to bupropion or escitalopram.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Depressive Symptoms as Measured by Hamilton Rating Scale for Depression (HAM-D 17)</title>
        <description>Last summary score rating on the 17-item Hamilton Rating Scale for Depression Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Range 0-58.
0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression
≥ 23 = Very Severe Depression</description>
        <time_frame>12 weeks</time_frame>
        <population>age 18-65 with MDD, non-bipolar, non-psychotic, non-substance abusing, without intolerance to study drugs or adequate SSRI/bupropion treatment in current episode; physically healthy without contraindications to bupropion or escitalopram.</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram + Bupropion</title>
            <description>escitalopram plus bupropion XL</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram</title>
            <description>escitalopram monotherapy</description>
          </group>
          <group group_id="O3">
            <title>Bupropion</title>
            <description>bupropion XL monotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Depressive Symptoms as Measured by Hamilton Rating Scale for Depression (HAM-D 17)</title>
          <description>Last summary score rating on the 17-item Hamilton Rating Scale for Depression Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. Range 0-58.
0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression
≥ 23 = Very Severe Depression</description>
          <population>age 18-65 with MDD, non-bipolar, non-psychotic, non-substance abusing, without intolerance to study drugs or adequate SSRI/bupropion treatment in current episode; physically healthy without contraindications to bupropion or escitalopram.</population>
          <units>units on Hamilton Rating Scale for Depre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="8"/>
                    <measurement group_id="O2" value="9" spread="7"/>
                    <measurement group_id="O3" value="12" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To test the hypothesis that escitalopram + bupropion would have superior efficacy relative to each monotherapy, the group receiving both medications was separately compared to each monotherapy group, covarying for baseline score and country</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0916</p_value>
            <p_value_desc>escitalopram + bupropion vs. escitalopram: F(1,159) = 1.93, ns escitalopram + bupropion vs. bupropion: F (1,157) = 1.99, ns</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>adjusting for baseline score and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functioning, as Measured by the Social Adjustment Scale (SAS) Summary Score</title>
        <description>Social adjustment was measured using the Social Adjustment Scale (SAS). The SAS is a self-report scale that assesses depressive symptoms and functioning in nine social and work-related domains generating a total score that is indicative of a subject's overall level of social adjustment. Subjects rate their own social functioning over times on a 5-point scale on items covering work for pay, housework, extended family, parenting, marital status, social activity and leisure, family unit and student status (sub-scales). Mean values of all the sub-scales are used, with a range from 0-5. Higher score = worse outcome … worse functioning</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients; latest available Total SAS score used if week 12 score not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram + Bupropion</title>
            <description>escitalopram plus bupropion XL as dual treatment (i.e., this is not a SINGLE treatment arm; all patients assigned this arm received both medications)
escitalopram + bupropion: same dosing schedule as for monotherapy</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram</title>
            <description>escitalopram monotherapy
escitalopram: 10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted</description>
          </group>
          <group group_id="O3">
            <title>Bupropion</title>
            <description>bupropion XL monotherapy
bupropion XL: 150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted</description>
          </group>
        </group_list>
        <measure>
          <title>Functioning, as Measured by the Social Adjustment Scale (SAS) Summary Score</title>
          <description>Social adjustment was measured using the Social Adjustment Scale (SAS). The SAS is a self-report scale that assesses depressive symptoms and functioning in nine social and work-related domains generating a total score that is indicative of a subject's overall level of social adjustment. Subjects rate their own social functioning over times on a 5-point scale on items covering work for pay, housework, extended family, parenting, marital status, social activity and leisure, family unit and student status (sub-scales). Mean values of all the sub-scales are used, with a range from 0-5. Higher score = worse outcome … worse functioning</description>
          <population>All randomized patients; latest available Total SAS score used if week 12 score not available.</population>
          <units>units on the SAS scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread=".69"/>
                    <measurement group_id="O2" value="2.63" spread=".69"/>
                    <measurement group_id="O3" value="2.74" spread=".71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (SF)</title>
        <description>The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) intends to measure quality of life in 16 domains. A summary score is computed by adding the scores and dividing by 16 (or the number of answered items if some are not answered).
The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70. Higher score means more satisfaction.</description>
        <time_frame>12 weeks</time_frame>
        <population>All Randomized Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram + Bupropion</title>
            <description>escitalopram plus bupropion XL</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram</title>
            <description>escitalopram monotherapy</description>
          </group>
          <group group_id="O3">
            <title>Bupropion</title>
            <description>bupropion XL monotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (SF)</title>
          <description>The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) intends to measure quality of life in 16 domains. A summary score is computed by adding the scores and dividing by 16 (or the number of answered items if some are not answered).
The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70. Higher score means more satisfaction.</description>
          <population>All Randomized Subjects</population>
          <units>units on the Q-LES-Q scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread=".82"/>
                    <measurement group_id="O2" value="3.0" spread=".76"/>
                    <measurement group_id="O3" value="3.1" spread=".74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>A modified Systematic Assessment for Treatment Emergent Events (SAFTEE) at each visit specifically asked about 17 items (too much energy, muscle tightness, insomnia, tremor, poor concentration, word finding, spacy, dizzy, headache, dry mouth, decreased appetite, nausea, low energy, sleepy, sweating, decreased libido, anger/irritability) a pilot study showed occurred in at least 10% of patients treated with escitalopram plus bupropion. A General Inquiry then asked re additional symptoms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram + Bupropion</title>
          <description>escitalopram plus bupropion XL
escitalopram + bupropion: same dosing schedule as for monotherapy</description>
        </group>
        <group group_id="E2">
          <title>Escitalopram</title>
          <description>escitalopram monotherapy
escitalopram: 10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted</description>
        </group>
        <group group_id="E3">
          <title>Bupropion</title>
          <description>bupropion XL monotherapy
bupropion XL: 150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Too much energy</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="dizzy">dizzy</sub_title>
                <description>feeling dizzy, lightheaded or faint</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="78"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="84"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="dry mouth">dry mouth</sub_title>
                <description>dry mouth</description>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="78"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="84"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="decreased appetite">decreased appetite</sub_title>
                <description>anorexia</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="78"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="84"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="nausea, vomiting">nausea, vomiting</sub_title>
                <description>nausea, vomiting, queasy stomach</description>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="78"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="84"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Too much energy</sub_title>
                <description>A feeling of being too &quot;revved up&quot;</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="insomnia">insomnia</sub_title>
                <description>trouble falling asleep, staying asleep or waking too early</description>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="78"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="84"/>
                <counts group_id="E3" events="31" subjects_affected="31" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="lethargy">lethargy</sub_title>
                <description>low energy, lack of &quot;get up and go&quot;</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="84"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="sweating">sweating</sub_title>
                <description>sweating too much, excessive perspiration</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="78"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="84"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="sexual dysfunction">sexual dysfunction</sub_title>
                <description>delayed orgasm, anorgasmia, erectile dysfunction, poor libido, low sex drive</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="78"/>
                <counts group_id="E2" events="28" subjects_affected="18" subjects_at_risk="84"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="muscle tightness">muscle tightness</sub_title>
                <description>a feeling of tenseness or tightness in the muscles</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="78"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="84"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="tremor">tremor</sub_title>
                <description>involuntary shaking or trembling</description>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="78"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="84"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="cognitive disturbanc">trouble thinking</sub_title>
                <description>trouble thinking or concentrating, cognitive disturbance</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="84"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="trouble finding word">trouble finding words</sub_title>
                <description>word finding difficulty</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="spacey">spacey</sub_title>
                <description>feeling &quot;spacey&quot;, &quot;out of it&quot;, &quot;fuzzy headed&quot;, &quot;cotton in my head&quot;</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="78"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="84"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="headache">headache</sub_title>
                <description>pain inside the head</description>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="78"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="84"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="daytime sleepiness">daytime sleepiness</sub_title>
                <description>daytime sleepiness, feeling sleepy or groggy during the day</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="78"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="84"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="anger, irritability">anger, irritability</sub_title>
                <description>anger, irritability, feeling like &quot;flying off the handle&quot;, too touchy</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size may have limited demonstration of differences.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jonathan W. Stewart, M.D.</name_or_title>
      <organization>NYSPInstitute</organization>
      <phone>212-543-5745</phone>
      <email>jws6@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

